Renal denervation after the symplicity HTN-3 trial

Postepy w Kardiologii Interwencyjnej

Volumn 10, Issue 2, 2014, Pages 75-77

  Warchoł Celińska, Ewa ^a   Januszewicz, Andrzej ^a   Prejbisz, Aleksander ^a   Ka̧dziela, Jacek ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; VASODILATOR AGENT;

BLOOD PRESSURE; FOLLOW UP; HUMAN; KIDNEY ANGIOGRAPHY; KIDNEY DENERVATION; KIDNEY NERVE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; SAFETY; SHAM PROCEDURE; SYMPATHETIC NERVE; SYMPLICITY HTN 3 TRIAL;

EID: 84903995191     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2014.43509     Document Type: Review

References (14)

1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
2. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989; 67: 858-64.
3. Kon V. Neural control of renal circulation. Miner Electrolyte Metab 1989; 15: 33-43.
4. Kadziela J, Florczak E, Januszewicz A, Witkowski A. Denerwacja nerek-nowa metoda leczenia opornego nadciśnienia tȩtniczego. Postep Kardiol Inter 2010; 6: 173-6.
5. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
6. Krum H, Schlaich M, Sobotka PA, et al. TCT-12 long-termfollow-up of catheter-based renal denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol 2012; 60: doi: 10.1016/j.jacc.2012. 08.017.
7. Mahfoud F, Luscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34: 2149-57.
8. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-41.
9. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
10. Bhatt DL, Kandzari DE, O'Neill WW, et al. (SYMPLICITYHTN-3 Investigators). A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-401.
11. Luscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITYHTN-3: confused at the higher level? Eur Heart J 2014 May 14. pii: ehu195 [Epub ahead of print].
12. Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med 2014; 370: 1454-7.
13. Worthley SG, Tsioufis CP, Worthley MI. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34: 2132-40.
14. Jin Y, Jacobs L, Baelen M, et al. (Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) investigators). Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press 2014; 23: 138-46.